Drug intelligence / Profile preview

VRG-145

Development stage: Preclinical
Lead developer: Novamigra
Modality: Small Molecules
Administration: Oral

Overview

**VRG-145** is an oral, small-molecule fixed-dose combination being developed by VRG Therapeutics and its spinout Novamigra Therapeutics for preventive treatment of migraine. The program combines an N-methyl-D-aspartate receptor antagonist with an agent that inhibits the renin-angiotensin system, thereby addressing neuronal excitability and vascular biology implicated in migraine. The specific active ingredients have not been publicly disclosed. Sponsor-reported animal studies showed synergistic pain-relieving activity relative to the individual components. ([vrgtherapeutics.com](https://www.vrgtherapeutics.com/news-articles/vrg-therapeutics-advances-vrg-145))

Targets

ACE (Angiotensin Converting Enzyme)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on VRG-145.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRG-145.

Explore the full profile